Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  ElZarrad, M Khair ^a,b   Mukhopadhyay, Partha ^c   Mohan, Nishant ^a   Hao, Enkui ^c   Dokmanovic, Milos ^a   Hirsch, Dianne S ^a   Shen, Yi ^a   Pacher, Pal ^c   Wu, Wen Jin ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; ALBUMIN D SITE BINDING PROTEIN; ARYL HYDROCARBON NUCLEAR TRANSLOCATOR LIKE; ATRIAL MYOSIN LIGHT CHAIN 1; ATRIAL NATRIURETIC FACTOR; BASIC HELIX LOOP HELIX FAMILY MEMBER E40; BASIC HELIX LOOP HELIX FAMILY MEMBER E41; BIOLOGICAL MARKER; CONNECTIN; F BOX AND LEUCINE RICH REPEAT PROTEIN 7; FIBROBLAST GROWTH FACTOR HOMOLOGOUS FACTOR 1; MYOSIN LIGHT CHAIN; MYOSIN LIGHT CHAIN 1; MYOSIN LIGHT CHAIN 2A; MYOSIN LIGHT POLYPEPTIDE 4; MYOSIN LIGHT POLYPEPTIDE 7; NEURONAL PER ACRYL HYDROCARBON NUCLEAR TRANSLOCATOR; PERIOD HOMOLOGUE 1; PROTEIN; RELAXIN FAMILY PEPTIDE RECEPTOR 1; SARCOLIPIN; TRASTUZUMAB; TROPONIN I; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DNA REPAIR; ECHOCARDIOGRAPHY; ELECTRON MICROSCOPY; GENE; GENE EXPRESSION; HEART FUNCTION; HEART LEFT VENTRICLE PERFORMANCE; HEART MITOCHONDRION; HEART MUSCLE CELL; MICROARRAY ANALYSIS; MOUSE; MYOCARDIAL GENE; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; CASPASE 3; CASPASE 7; DNA REPAIR; HEART; HEART VENTRICLES; HEMODYNAMICS; MICE; MITOCHONDRIA; MUSCLE CONTRACTION; MYOCYTES, CARDIAC; MYOSIN LIGHT CHAINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXIDATIVE STRESS; STRESS, PHYSIOLOGICAL; TRANSCRIPTOME; TROPONIN I;

EID: 84892576557     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079543     Document Type: Article

References (56)

1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792. doi:10.1056/ NEJM200103153441101. PubMed: 11248153.
2. Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN et al. (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study. J Natl Cancer Inst 104: 1293 -1305. doi:10.1093/jnci/djs317. PubMed: 22949432.
3. Telli ML, Witteles RM (2011) Trastuzumab-related cardiac dysfunction. J Natl Compr Canc Netw 9: 243-249. PubMed: 21310845.
4. Wu WJ, Dokmanovic M (2009) Trastuzumab. In: M Schwab. Encyclopedia of Cancer: Springer Reference. Springer-Verlag Berlin Heidelberg. doi: 10.1007/978-3-540-47648-1
5. Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339: 900-905. doi:10.1056/NEJM199809243391307. PubMed: 9744975.
6. Seidman A, Hudis C, Pierri MK, Shak S, Paton V et al. (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20: 1215-1221. doi:10.1200/JCO.20.5.1215. PubMed: 11870163.
7. Perez EA, Rodeheffer R (2004) Clinical cardiac tolerability of trastuzumab. J Clin Oncol 22: 322-329. PubMed: 14722042.
8. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL et al. (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: 710 -717. doi:10.7326/0003-4819-91-5-710. PubMed: 496103.
9. Di Cosimo S (2011) Heart to heart with trastuzumab: a review on cardiac toxicity. Targ Oncol 6: 189-195. doi:10.1007/s11523-011-0203-8. PubMed: 22125051.
10. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR et al. (2005) Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23: 7820-7826. doi:10.1200/JCO.2005.13.300. PubMed: 16258084.
11. Telli ML, Hunt SA, Carlson RW, Guardino AE (2007) Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 25: 3525-3533. doi:10.1200/JCO.2007.11.0106. PubMed: 17687157.
12. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M et al. (2010) Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28: 3910-3916. doi:10.1200/JCO.2009.27.3615. PubMed: 20679614.
13. Labugger R, Organ L, Collier C, Atar D, Van Eyk JE (2000) Extensive troponin I and T modification detected in serum from patients with acute myocardial infarction. Circulation 102: 1221-1226. doi:10.1161/01.CIR.102.11. 1221. PubMed: 10982534.
14. Melanson SE, Tanasijevic MJ, Jarolim P (2007) Cardiac Troponin Assays: A view from the clinical chemistry laboratory. Circulation 116: 501-504. doi:10.1161/CIRCULATIONAHA.107.722975. PubMed: 17967982.
15. Stejskal D, Lacnák B, Andelová K, Skvarilová M, Bartek J (2005) MLC-1 (myosin light chains-1) in differential diagnosis of dyspnea. Biomed Papers 149 pp. 89-91.
16. Hansen MS, Stanton EB, Gawad Y, Packer M, Pitt B et al. (2002) Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan. Am J Cardiol 90: 969-973. doi:10.1016/S0002-9149(02)02663-2. PubMed: 12398964.
17. Goto T, Takase H, Toriyama T, Sugiura T, Sato K et al. (2003) Circulating concentrations of cardiac proteins indicate the severity of congestive heart failure. Heart 89: 1303-1307. doi:10.1136/heart.89.11.1303. PubMed: 14594884.
18. DeCara JM (2012) Early detection of chemotherapy-related left ventricular dysfunction. Curr Cardiol Rep 14: 334-341. doi:10.1007/s11886-012-0256-z. PubMed: 22415395.
19. Negro A, Brar BK, Lee KF (2004) Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res 59: 1-12. doi:10.1210/rp.59.1.1. PubMed: 14749494.
20. Chan R, Hardy WR, Laing MA, Hardy SE, Muller WJ (2002) The catalytic activity of the ErbB-2 receptor tyrosine kinase is essential for embryonic development. Mol Cell Biol 22: 1073-1078. doi:10.1128/MCB.22.4.1073-1078.2002. PubMed: 11809799.
21. Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S et al. (2002) Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U-S-A 99: 8880-8885. doi:10.1073/pnas.122249299. PubMed: 12072561.
22. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S et al. (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8: 459-465. doi:10.1038/nm0502-459. PubMed: 11984589.
23. Pentassuglia L, Timolati F, Seifriz F, Abudukadier K, Suter TM et al. (2007) Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes. Exp Cell Res 313: 1588-1601. doi:10.1016/j.yexcr.2007.02.007. PubMed: 17400210.
24. Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM,Suter TM (2002) Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1 b and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 105: 1551-1554. doi:10.1161/01.CIR.0000013839.41224.1C. PubMed: 11927521.
25. Riccio G, Esposito G, Leoncini E, Contu R, Condorelli G et al. (2009) Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents. FASEB J 23: 3171-3178. doi:10.1096/fj.09-131383. PubMed: 19417081.
26. Fedele C, Riccio G, Coppola C, Barbieri A, Monti MG et al. (2011) Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. Breast Cancer Res Treat, 133: 511-21. doi:10.1007/s10549-011-1783-1789. PubMed: 21947749.
27. Sütsch G, Brunner UT, von Schulthess C, Hirzel HO, Hess OM et al. (1992) Hemodynamic performance and myosin light chain-1 expression in the hypertrophied left ventricle in aortic valve disease before and after valve replacement. Circ Res 70: 1035-1043. doi:10.1161/01.RES.70.5.1035. PubMed: 1533180.
28. Grimm M, Haas P, Willipinski-Stapelfeldt B, Zimmermann WH, Rau T et al. (2005) Key role of myosin light chain (MLC) kinase-mediated MLC2a phosphorylation in the α1-adrenergic positive inotropic effect in human atrium. Cardiovasc Res 65: 211-220. doi:10.1016/j.cardiores.2004.09.019. PubMed: 15621049.
29. Huang C, Sheikh F, Hollander M, Cai C, Becker D et al. (2003) Embryonic atrial function is essential for mouse embryogenesis, cardiac morphogenesis and angiogenesis. Development 130: 6111-6119. doi:10.1242/dev.00831. PubMed: 14573518.
30. Wang D, Oparil S, Feng JA, Li P, Perry G et al. (2003) Effects of Pressure Overload on Extracellular Matrix Expression in the Heart of the Atrial Natriuretic Peptide-Null Mouse. Hypertension 42: 88-95. doi: 10.1161/01.HYP.0000074905.22908.A6. PubMed: 12756220.
31. Herman DS, Lam L, Taylor MR, Wang L, Teekakirikul P et al. (2012) Truncations of titin causing dilated cardiomyopathy. N Engl J Med 7: 619-628. PubMed: 22335739.
32. Gramlich M, Michely B, Krohne C, Heuser A, Erdmann B et al. (2009) Stress-induced dilated cardiomyopathy in a knock-in mouse model mimicking human titin-based disease. J Mol Cell Cardiol 3: 352-358.
33. Bathgate RA, Halls ML, van der Westhuizen ET, Callander GE, Kocan M et al. (2013) Relaxin family peptides and their receptors. Physiol Rev 93: 405-480. doi:10.1152/physrev.00001.2012. PubMed: 23303914.
34. Dschietzig T, Teichman S, Unemori E, Wood S, Boehmer J et al. (2009) Intravenous recombinant human Relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamics trial. J Card Fail 15: 182-190. doi:10.1016/j.cardfail.2009.01.008. PubMed: 19327619.
35. Shanmugam M, Molina CE, Gao S, Severac-Bastide R, Fischmeister R et al. (2011) Decreased sarcolipin protein expression and enhanced sarco(endo)plasmic reticulum Ca2+ uptake in human atrial fibrillation. Biochem Biophys Res Commun 410: 97-101. doi:10.1016/j.bbrc.2011.05.113. PubMed: 21640081.
36. Nakayama F, Müller K, Hagiwara A, Ridi R, Akashi M et al. (2008) Involvement of intracellular expression of FGF12 in radiation-induced apoptosis in mast cells. J Radiat Res 48: 491-501. PubMed: 18525161.
37. Liu CJ, Dib-Hajj SD, Renganathan M, Cummins TR,Waxman SG (2003) Modulation of the cardiac sodium channel nav1.5 by fibroblast growth factor homologous factor 1b. J Biol Chem 278: 1029-1036. doi:10.1074/jbc.M207074200. PubMed: 12401812.
38. Wang X, Pankratz VS, Fredericksen Z, Tarrell R, Karaus M et al. (2010) Common variants associated with breast cancer in genomewide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 19: 2886-2897. doi:10.1093/hmg/ddq174. PubMed: 20418484.
39. Coon TA, Glasser JR, Mallampalli RK, Chen BB (2012) Novel E3 ligase component FBXL7 ubiquitinates and degrades Aurura A, causing mitotic arrest. Cell Cycle 11: 721-729. doi:10.4161/cc.11.4.19171. PubMed: 22306998.
40. Turchi L, Aberdam E, Mazure N, Pouysségur J, Deckert M et al. (2008) Hif- 2 alpha mediates UV-induced apoptosis through a novel ATF3-dependent death pathway. Cell Death Differ 15: 1472-1480. doi:10.1038/cdd.2008.74. PubMed: 18511933.
41. Okamoto Y, Chaves A, Chen J, Kelley R, Jones K et al. (2001) Transgenic mice with cardiac-specific expression of activating transcription factor 3, a stress-inducible gene, have conduction abnormalities and contractile dysfunction. Am J Pathol 159: 639-650. doi:10.1016/S0002-9440(10)61735-X. PubMed: 11485922.
42. Curtis AM, Cheng Y, Kapoor S, Reilly D, Price TS et al. (2007) Circadian variation of blood pressure and the vascular response to asynchronous stress. Proc Natl Acad Sci U-S-A 104: 3450-3455. doi:10.1073/pnas.0611680104. PubMed: 17360665.
43. Wang Q, Maillard M, Schibler U, Burnier M, Gachon F (2010) Cardiac hypertrophy, low blood pressure, and low aldosterone levels in mice devoid of the three circadian PAR bZip transcription factors DBP, HLF, and TEF. Am J Physiol Regul Integr Comp Physiol 4: 1013-1019.
44. Ritchie A, Gutierrez O,Fernandez-Luna JL (2009) PAR bZIP-bik is a novel transcriptional pathway that mediates oxidative stress-induced apoptosis in fibroblasts. Cell Death Differ 16: 838-846. doi:10.1038/cdd.2009.13. PubMed: 19219069.
45. Stow LR, Richards J, Cheng KY, Lynch IJ, Jeffers LA et al. (2012) The Circadian Protein Period 1 Contributes to Blood Pressure Control and Coordinately Regulates Renal Sodium Transport Genes. Hypertension 6: 1151-1156. PubMed: 22526258.
46. Wang NN, Yang G, Jia Z, Zhang H, Aoyagi T et al. (2008) Vascular PPAR gamma Controls Circadian Variation in Blood Pressure and Heart Rate through Bmal1. Cell Metab 8: 482-491. doi:10.1016/j.cmet.2008.10.009. PubMed: 19041764.
47. Lee J, Kim MS, Li R, Liu VY, Fu L et al. (2011) Loss of Bmal1 leads to uncoupling and impaired glucose-stimulated insulin secretion in β-cells. Islets 3: 381-388. doi:10.4161/isl.3.6.18157. PubMed: 22045262.
48. Hopcroft LE, McBride MW, Harris KJ, Sampson AK, McClure JD et al. (2010) Predictive response-relevant clustering of expression data provides insights into disease processes. Nucleic Acids Res 38: 6831-6840. doi:10.1093/nar/gkq550. PubMed: 20571087.
49. Riley P, Anson-Cartwright L,Cross JC (1998) The Hand1 bHLH transcription factor is essential for placentation and cardiac morphogenesis. Nat Genet 18: 271-275. doi:10.1038/ng0398-271. PubMed: 9500551.
50. Ritter O, Bottez N, Burkard N, Schulte HD, Neyses L (2002) A molecular mechanism improving the contractile state in human myocardial hypertrophy. Exp Clin Cardiol 7: 151-157. PubMed: 19649240.
51. Su W, Xie Z, Guo Z, Duncan MJ, Lutshumba J et al. (2012) Altered clock gene expression and vascular smooth muscle diurnal contractile variations in type 2. Am J Physiol Heart Circ Physiol 3: 621-633.
52. Pacher P, Beckman JS, Liaudet L (2007) Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87: 315-424. doi:10.1152/physrev.00029.2006. PubMed: 17237348.
53. Pacher P, Schulz R, Liaudet L, Szabó C (2005) Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol Sci 26: 302-310. doi:10.1016/j.tips.2005.04.003. PubMed: 15925705.
54. Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S et al. (2011) The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 57: 2263-2270. doi:10.1016/j.jacc.2010.11.063. PubMed: 21616287.
55. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B et al. (2012) Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 5: 596-630. doi:10.1161/CIRCIMAGING.112.973321. PubMed: 22744937.
56. Barth AS, Zhang Y, Li T, Smith RR, Chimenti I et al. (2012) Functional impairment of human resident cardiac stem cells by the cardiotoxic antineoplastic agent trastuzumab. Stem Cells Trans Med 1: 289-297.